VivoSeq
Oncology

Advanced Microsatellite Stable Colorectal Cancer

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Advanced Microsatellite Stable Colorectal Cancer is an early-stage landscape with 4 programs across 3 companies. The most active players are Gilead, Bristol-Myers Squibb, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Denikitug

Gilead

Nivolumab

Bristol-Myers Squibb

Bevacizumab

Bio-Thera Solutions

Trifluridine-Tipiracil

Merck & Co.

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Recruiting·Gilead logoGilead·Phase 2·NCT07527858·170 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)